Dexcom moved Wednesday to accelerate the commercial rollout of its Stelo continuous glucose monitor following the FDA's landmark clearance expanding the device's indication to pediatric users — making it the first over-the-counter CGM approved for children in the United States. The San Diego-based medical device company confirmed distribution agreements with major pharmacy chains including CVS Health, Walgreens, and Walmart to ensure the device reaches families without a prescription requirement.

The FDA's decision, announced Tuesday, represents a significant regulatory milestone that removes a longstanding barrier for parents managing blood glucose monitoring in children outside of clinical settings. Until now, CGM access for younger patients required a physician's prescription and was largely confined to type 1 diabetes diagnoses covered by insurance. The Stelo's OTC status opens access to a broader population, including children with prediabetes or those whose parents seek non-invasive monitoring options.

Pediatric endocrinologists and patient advocacy groups, including JDRF and the American Diabetes Association, welcomed the expanded clearance but urged parents to consult healthcare providers before initiating unsupervised monitoring regimens. Dr. Jennifer Sherr of Yale School of Medicine noted that while the technology is safe, clinical context remains important for interpreting glucose data in developing children.

Analysts at Jefferies and Morgan Stanley raised their Dexcom price targets Wednesday morning, citing the pediatric OTC indication as a material expansion of the total addressable market. Competitors Abbott Laboratories, maker of the FreeStyle Libre, and Senseonics are expected to face pressure to seek similar pediatric OTC designations for their own devices.

Dexcom CEO Kevin Sayer stated in a release that the company would offer a patient support program pairing Stelo users with digital coaching tools, aiming to convert first-time OTC buyers into long-term platform subscribers. The company projected that the pediatric indication could add several hundred thousand new users to its active base within the first twelve months of expanded availability.